|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Isao_Teshirogi
|
|
gptkbp:collaboratedWith
|
gptkb:Roche
gptkb:H_Lundbeck
gptkb:ViiV_Healthcare
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:founded
|
1878
|
|
gptkbp:founder
|
gptkb:Shobei_Shionogi
|
|
gptkbp:headquarters_location
|
gptkb:Osaka
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Shionogi
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:JapaneseName
|
gptkb:塩野義製薬株式会社
|
|
gptkbp:location
|
gptkb:Doshomachi,_Chuo-ku,_Osaka,_Japan
|
|
gptkbp:logo
|
Shionogi logo.svg
|
|
gptkbp:market
|
global
|
|
gptkbp:notableContributor
|
gptkb:HIV/AIDS
antibiotics
infectious diseases
oncology
pain management
cardiovascular diseases
|
|
gptkbp:notableEvent
|
developed COVID-19 oral antiviral pill
listed on Nikkei 225
partnered with Roche for Xofluza
|
|
gptkbp:notableProduct
|
gptkb:Fetroja
gptkb:Crestor
gptkb:Xofluza
|
|
gptkbp:numberOfEmployees
|
5,000+
|
|
gptkbp:parentCompany
|
none (independent)
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:revenue_(FY2022)
|
~$3.5 billion USD
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4507
|
|
gptkbp:subsidiary
|
gptkb:Shionogi_B.V.
gptkb:Shionogi_Inc.
|
|
gptkbp:type
|
public (K.K.)
|
|
gptkbp:website
|
https://www.shionogi.com
|
|
gptkbp:主要业务
|
research and development of prescription drugs
|
|
gptkbp:bfsParent
|
gptkb:NOVN
|
|
gptkbp:bfsLayer
|
5
|